Permanent Capital Management LP Invests $909,000 in Becton, Dickinson and Company $BDX

Permanent Capital Management LP bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,684 shares of the medical instruments supplier’s stock, valued at approximately $909,000.

Several other hedge funds and other institutional investors also recently modified their holdings of BDX. Wellington Management Group LLP boosted its position in Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after acquiring an additional 5,174,944 shares in the last quarter. Norges Bank bought a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $653,377,000. Laurel Wealth Advisors LLC lifted its stake in shares of Becton, Dickinson and Company by 16,974.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock valued at $272,049,000 after purchasing an additional 1,570,136 shares during the period. First Eagle Investment Management LLC lifted its stake in shares of Becton, Dickinson and Company by 13.8% in the 3rd quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock valued at $1,870,653,000 after purchasing an additional 1,208,218 shares during the period. Finally, Brandes Investment Partners LP bought a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $150,051,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.4%

NYSE BDX opened at $154.35 on Friday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The stock’s fifty day moving average price is $185.53 and its 200-day moving average price is $188.82. The stock has a market cap of $43.95 billion, a P/E ratio of 25.18, a P/E/G ratio of 11.17 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same quarter in the previous year, the firm earned $3.43 EPS. Becton, Dickinson and Company’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Insider Activity at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 2,787 shares of company stock worth $551,391. Insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on BDX shares. Royal Bank Of Canada set a $172.00 price objective on Becton, Dickinson and Company in a report on Tuesday, February 10th. Morgan Stanley upped their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Bank of America increased their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research note on Monday, January 5th. Citigroup lowered their price target on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Finally, Wells Fargo & Company cut their price objective on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus price target of $195.46.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.